Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

IBUPROFEN

All products: general benefit

Other products in the same Health Canada class (M01AE) — coverage varies; not interchangeable

  • Flurbiprofen (Ansaid): general benefit, Not a benefit
  • Ketoprofen (Ketoprofen): general benefit, Not a benefit
  • Naproxen (Naprosyn E): general benefit, Not a benefit
  • Tiaprofenic acid (Surgam): general benefit, Not a benefit
  • Esomeprazole + naproxen (Vimovo): not a benefit
  • Naproxen (Teva-Naproxen Sodium): not a benefit

12 more in the class list below

Motrin · DIN 00364142 · 400mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-14 — choose a marketed DIN from the same-category list.Discontinued 2002-05-14 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2002-05-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Motrin · DIN 00364142 Manufacturer: The Upjohn Company of Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-05-14 · brand MOTRIN TABLETS 400MG · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 400 MG · company Mcneil consumer healthcare division of johnson & johnson inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Ministry pays: $0.0468 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2903 · Verify on the e-Formulary ↗ (DIN 00364142)

Source record
DIN 00364142: Motrin Raw flags: sec3=Y Item: 280804021; group id 382; item number 0913; lccId None; manufacturer id UPJ Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.1871; ministry $0.0468 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00364142 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2903 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00506052 · $0.0468 Ibuprofen · DIN 02317338 · $0.0468
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2002-05-14 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, NAPROXEN, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

TIAPROFENIC ACID

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 200mg, 300mg · Tab

NAPROXEN & ESOMEPRAZOLE MAGNESIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 375mg & 20mg, 500mg & 20mg · MR Tab

NAPROXEN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 275mg, 550mg · Tab

OXAPROZIN.

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 600mg · Tab

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-IBUPROFEN and APO-IBUPROFEN CAPLET (ibuprofen tablets) are indicated for fast and effective relief of: • headache pain (including mild to moderate migraine and tension headache) • menstrual pain • toothache (dental pain) • pain from inflammation associated with conditions including: ▪ arthritis ▪ physical or athletic overexertion, (e.g., sprains or strains) • minor aches and pains in muscles, bones and joints • backache • the aches and pain due to the common cold and flu • reduction of fever 1.1 Pediatrics Pediatrics (<12 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggest that use in the geriatric population is associated with differences in safety or effectiveness and a brief discussion can be found in the appropriate sections (e.g., Warnings and Precautions). https://pdf.hres.ca/dpd_pm/00078209.PDF PM date: JAN 07, 2025 Source product: APO-IBUPROFEN; DIN 00441643; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.